ImmunityBio Secures $75M Financing Under Royalty Interest Purchase Agreement With Oberland Capital; $25M Converted Principal Amount From Nant Capital

ImmunityBio, Inc. (NASDAQ: IBRX) has secured $75 million in non-dilutive financing through an amended Royalty Interest Purchase Agreement (RIPA) with Oberland Capital, raising the total committed capital under the agreement to $375 million. Additionally, Nant Capital, LLC converted a $25 million principal amount into 4.6 million shares of common stock, which will reduce the company's debt under a $505 million Promissory Note due in December 2024.